Thus, our data suggest that assays against IFN-α2 and IFN-ω may become the antibody tests of choice, since they were so clearly positive even in patients lacking the other antibodies associated with APS1 [23]. Here, IFNA2 is linked to autoimmune polyendocrine syndrome type 1.